Latest Aminolevulinic acid Stories
Neurosurgeons from UC San Francisco describe the use of 5-aminolevulinic acid (5-ALA) fluorescence in guiding resection of recurrent glioblastoma multiforme (GBM). Ingestion of 5-ALA by a patient before surgery leads to fluorescence of tumor cells intraoperatively in response to certain wavelengths of light. This can provide information not necessarily available through magnetic resonance imaging (MRI), the standard mode of imaging used to detect primary and recurrent GBMs. The additional...
Bright color distinguishes tumor from healthy tissue to improve tumor resection Just 24 hours after Lisa Rek sang at her niece's wedding, her husband Brad was driving her to a local hospital. "The pain got worse. When we got to the emergency room, I said to Brad 'something is just not right,'" Rek remembers. After an MRI showed a suspected tumor, Rek was immediately flown to Seidman Cancer Center at University Hospitals (UH) Case Medical Center, where Andrew Sloan, MD, diagnosed her...
CLEVELAND, Dec. 1, 2011 /PRNewswire/ -- Just 24 hours after Lisa Rek sang at her niece's wedding, her husband Brad was driving her to a local hospital. "The pain got worse. When we got to the emergency room, I said to Brad 'something is just not right,'" Rek remembers. After an MRI showed a suspected tumor, Rek was immediately flown to Seidman Cancer Center at University Hospitals (UH) Case Medical Center, where Andrew Sloan, MD, diagnosed her with Stage 4 glioblastoma, the...
OSLO, Norway, September 27, 2011 /PRNewswire/ -- - Strategic collaboration with Ipsen for marketing rights in Europe and the rest of the world except Nordics and the US - Photocure to commercialise the product directly in the US market Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today the execution of a new commercial strategy for Hexvix, its...
"These abstracts clearly confirm a role of PDT in the treatment of head and neck cancer. The inclusion of our abstracts in this year's IPA's World Congress 2011 is an important accomplishment for our Company as it reflects the high quality of research and the IPA's interest in our technology," said Carolyn Cross, Chairman & CEO of Ondine Biomedical Inc. Vancouver, British Columbia (PRWEB) June 06, 2011 Ondine Biomedical Inc (TSX: OBP; AIM: OBP; the "Company"), is dedicated to the...
New LED device may help advance photodynamic therapy for skin cancerCan skin cancer be treated with light? Scientists at the University of California, Irvine (UC Irvine), believe so. They're exploring new ways to image cancerous lesions using LEDs that might advance a technique for treating cancer called photodynamic therapy (PDT) -- work that they will describe at the Optical Society's (OSA) 94th annual meeting, Frontiers in Optics (FiO) 2010 at the Rochester Riverside Convention Center in...
WILMINGTON, Mass., Aug. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(® )(Nasdaq: DUSA) reported today that on the afternoon of August 5, 2010 the U.S. Food and Drug Administration (FDA) notified DUSA that it has not granted Orphan Drug Designation for the use of Levulan(®) (aminolevulinic acid HCl) Photodynamic Therapy (PDT) for the prevention of cutaneous squamous cell carcinomas (SCCs) in patients who have a proven history of multiple localized cutaneous SCCs over a 12...
All Claims Upheld at Conclusion of Successful Reexamination Process WILMINGTON, Mass., June 24 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office (USPTO) has completed its re-examination of US Patent No. 5,079,262, "Method of detection and treatment of malignant and non-malignant lesions utilizing...
WILMINGTON, Mass., May 7 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U(®), Blue Light Photodynamic Therapy Illuminator. The new patent will have method of treatment claims which cover the...
PITTSBURGH, Feb. 18 /PRNewswire-USNewswire/ -- Neurosurgeons at Allegheny General Hospital (AGH) are exploring use of a drug that illuminates brain tumor cells to determine if the experimental visualization technique will enhance their ability to surgically excise tumors and improve patient survival. AGH is one of just three medical centers in the country approved by the U.S. Food and Drug Administration to investigate the efficacy of an oral fluorescent compound, called 5-aminoevulnic acid...
